Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | SPR | P35270 | 1/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242563 | 1.00 | GPR119 (0.57) | GPR119USP30SPRPIK3CDEPHX2 | |
| SCHEMBL30193463 | 1.00 | GPR119 (0.57) | GPR119USP30SPRPIK3CDEPHX2 | |
| SCHEMBL6305698 | 0.93 | GPR119 (0.53) | GPR119USP30SPRALDH1A1HTT | |
| SCHEMBL639943 | 0.93 | GPR119 (0.63) | GPR119USP30SPREPHX2ALDH1A1 | |
| SCHEMBL6306297 | 0.90 | GPR119 (0.53) | GPR119USP30SPREPHX2 | |
| SCHEMBL29548089 | 0.90 | GPR119 (0.53) | GPR119USP30SPREPHX2 | |
| SCHEMBL7466419 | 0.88 | GPR119 (0.54) | GPR119USP30SPRPIK3CD | |
| SCHEMBL12526598 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD | |
| SCHEMBL13128900 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD | |
| SCHEMBL18756989 | 0.85 | USP30 (0.56) | GPR119USP30PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186910-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116178391-A | Forward allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-109310668-B | Positive allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2023-01-24 | — | — | CN | disclosed |
| EP-3534901-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2022-06-22 | — | — | EP | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2501693-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB Pharma SAS (FR) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
| US-6888001-B2 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1107965-B1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | ORTHO MCNEIL PHARM INC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2003-11-06 | — | — | US | disclosed |
| US-6562847-B1 | Useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1107965-A1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010997-A1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | CHRM1, CHRM5, CHRM2 | GPR119 338/4885USP30 4398/4885SPR 1019/4885 |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | GPR119 3612/4885USP30 764/4885SPR 4306/4885 |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | GPR119 3612/4885USP30 764/4885SPR 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.